Shahbazi Khamas Shahriyar, Alizadeh Bahmani Amir Hossein, Vijverberg Susanne J H, Brinkman Paul, Maitland-van der Zee Anke H
Department of Pulmonary Medicine, Amsterdam UMC location, University of Amsterdam, Amsterdam, the Netherlands.
Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
ERJ Open Res. 2023 Aug 29;9(4). doi: 10.1183/23120541.00143-2023. eCollection 2023 Jul.
Asthma and COPD are among the most common respiratory diseases. To improve the early detection of exacerbations and the clinical course of asthma and COPD new biomarkers are needed. The development of noninvasive metabolomics of exhaled air into a point-of-care tool is an appealing option. However, risk factors for obstructive pulmonary diseases can potentially introduce confounding markers due to altered volatile organic compound (VOC) patterns being linked to these risk factors instead of the disease. We conducted a systematic review and presented a comprehensive list of VOCs associated with these risk factors.
A PRISMA-oriented systematic search was conducted across PubMed, Embase and Cochrane Libraries between 2000 and 2022. Full-length studies evaluating VOCs in exhaled breath were included. A narrative synthesis of the data was conducted, and the Newcastle-Ottawa Scale was used to assess the quality of included studies.
The search yielded 2209 records and, based on the inclusion/exclusion criteria, 24 articles were included in the qualitative synthesis. In total, 232 individual VOCs associated with risk factors for obstructive pulmonary diseases were found; 58 compounds were reported more than once and 12 were reported as potential markers of asthma and/or COPD in other studies. Critical appraisal found that the identified studies were methodologically heterogeneous and had a variable risk of bias.
We identified a series of exhaled VOCs associated with risk factors for asthma and/or COPD. Identification of these VOCs is necessary for the further development of exhaled metabolites-based point-of-care tests in these obstructive pulmonary diseases.
哮喘和慢性阻塞性肺疾病（COPD）是最常见的呼吸系统疾病。为了改善哮喘和COPD急性加重的早期检测及临床病程，需要新的生物标志物。将呼出气体的非侵入性代谢组学发展成为一种即时检测工具是一个有吸引力的选择。然而，由于挥发性有机化合物（VOC）模式的改变与这些风险因素而非疾病相关联，阻塞性肺疾病的风险因素可能会引入混杂标志物。我们进行了一项系统综述，并列出了与这些风险因素相关的VOC的综合清单。
在2000年至2022年期间，在PubMed、Embase和Cochrane图书馆进行了以PRISMA为导向的系统检索。纳入评估呼出气体中VOC的全文研究。对数据进行叙述性综合分析，并使用纽卡斯尔-渥太华量表评估纳入研究的质量。
检索得到2209条记录，根据纳入/排除标准，24篇文章纳入定性综合分析。总共发现了232种与阻塞性肺疾病风险因素相关的个体VOC；58种化合物被多次报道，12种在其他研究中被报道为哮喘和/或COPD的潜在标志物。批判性评价发现，所确定的研究在方法上存在异质性，且存在不同程度的偏倚风险。
我们确定了一系列与哮喘和/或COPD风险因素相关的呼出VOC。识别这些VOC对于在这些阻塞性肺疾病中进一步开发基于呼出代谢物的即时检测至关重要。
